感染症向け分子診断市場：カスタム型の予測・分析 (症候群別・プレックス別・診断現場別・国別)、新型コロナウイルス感染症 (Covid-19) の影響、エグゼクティブ向け提言 (2020～2024年)

新型コロナウイルス感染症 (Covid-19) の感染拡大の影響も受けて、世界の感染症向け分子診断の需要が急激に拡大しつつあります。マルチプレックス方式が手中となりつつある一方、微生物診断は消滅しつつあります。

当レポートでは、感染症向け分子診断の今後の技術進歩・市場成長の見通しについて分析し、技術的な概略や主な活用分野、今後の医療現場に及ぼす影響力、昨今の主な開発・製品上市の動き、主要企業のプロファイルと主力製品、今後の市場規模の動向見通し、地域別・症候群別・プレックス別・診断現場別の詳細動向、新型コロナウイルス感染症 (Covid-19) 発生の影響、といった情報を取りまとめてお届けいたします。

目次

i. 感染症向け分子診断市場：戦略的状況分析とCovid-19の影響

ii. エグゼクティブ・マーケティング・販売・ビジネス開発スタッフ向け提言

iii. 経営コンサルタント・投資顧問向け提言

第1章 イントロダクション、市場の定義

第2章 感染症：疾患別の市場分析

• HIV-ヒト免疫不全ウイルス（AIDS）
  • 病因、疫学
  • 診断・検査方法
  • 市場機会の分析
• HBV-B型肝炎
• HCV-C型肝炎
• HPV-ヒトパピローマウイルス
• インフルエンザ
• CTGC-クラミジア/淋病
• 結核
• MRSA-メチシリン耐性黄色ブドウ球菌
• VRE-バンコマイシン耐性腸球菌
• 血液スクリーニング
• 新型コロナウイルス感染症 (Covid-19)
• パンデミック診断

第3章 業界の概要

• 主な市場参入企業
  • 教育・研究機関
  • 診断検査の開発業者
  • 計測装置のサプライヤー
  • 試薬の流通業者・サプライヤー
  • 独立系の検査室
  • 国営／公営の検査室
  • 院内検査室
  • 開業医
  • 監査機関
  • 認証機関
• 臨床検査室の内訳
  • 従来型の市場区分
  • 研究室の焦点と内訳
• 産業構造
  • 病院の検査シェア
  • 規模の経済
  • 開業医
  • 医師とPOCT
• 主要な分子診断企業のプロファイル
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Beckman Coulter
  • Biocartis
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Chembio
  • Curetis
  • Diagenode Diagnostics
  • DiaSorin
  • 栄研化学
  • Fusion Genomics.
  • Genedrive
  • GenePOC Diagnostics
  • GenMark Dx
  • Grifols
  • Hologic
  • Illumina
  • Inflammatix
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • Luminex
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore Technologies
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Seegene
  • Siemens Healthineers
  • T2 Biosystems
  • Thermo Fisher
  • Veramarx
  • XCR Diagnostics

第4章 市場動向

• 市場成長の促進要因
• 市場成長の抑制要因
• 計装と自動化
• 診断技術の動向
  • 敗血症検査市場-新しい方向性？
  • 創造的破壊要因としてのPOCT /自己検査
  • 遺伝学の遊び-すべての既知の感染症に対応できる検査手法
  • 抗生物質耐性遺伝子-診断の簡素化

第5章 感染症向け分子診断：昨今の進捗状況

• 当セクションの重要性と活用方法

第6章 世界の感染症向け分子診断市場

• 国別分析：概要
• 症候群別分析：概要
• プレックス (増幅方式) 別分析：概要
• 診断現場別分析：概要

第7章 世界の感染症向け分子診断市場：症候群別

• 呼吸器
• 胃腸
• 血液
• 髄膜炎/脳炎
• 性感染症
• その他

第8章 世界の感染症向け分子診断市場：プレックス別

• シングルプレックス
• デュプレックス
• トリプレックス
• マルチプレックス

第9章 世界の感染症向け分子診断市場：診断現場別

• 院内検査室
• 外来検査室
• POC (ポイントオブケア) 診断
• その他

付録

Table of Tables

• Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
• Table 2 Classification of HIV Species
• Table 3 HIV Tests - CMS Codes & Prices
• Table 4 Current HIV Molecular Tests and Instruments Used
• Table 5 HBV Tests - CMS Codes & Prices
• Table 6 HCV Tests - CMS Codes & Prices
• Table 7 HPV Clearance Rates
• Table 8 HPV Tests - CMS Codes & Prices
• Table 9 HPV Tests, Technology, Types
• Table 10 Types of Influenza Tests
• Table 11 Influenza Tests - CMS Codes & Prices
• Table 12 FDA Cleared Molecular Assays for Influenza
• Table 13 FDA Cleared NAAT CTGC Tests
• Table 14 CTGC NAAT Target Sequences and Possible False Reactions
• Table 15 CTGC Tests - CMS Codes & Prices
• Table 16 FDA Approved MDx Tests for Tuberculosis
• Table 17 Tuberculosis Tests - CMS Codes & Prices
• Table 18 FDA Approved Tests for MRSA
• Table 19 MRSA Tests - CMS Codes & Prices
• Table 20 FDA Approved Tests for VRE
• Table 21 VRE Tests - CMS Codes & Prices
• Table 22 FDA Approved Multiplex Assays
• Table 23 Characteristics of Coronavirus Pandemic Infections
• Table 24 COVID-19 Symptoms
• Table 25 Market Players by Type
• Table 26 Clinical Laboratory Departments and Segments
• Table 27 Laboratory Management Focus - Different Approaches
• Table 28 Key Segmentation Variables Going Forward
• Table 29 Five Factors Driving Growth
• Table 30 Four Factors Limiting Growth
• Table 31 Key Diagnostic Laboratory Technology Trends
• Table 32 - Global Market by Region
• Table 33 Global Market by Syndrome
• Table 34 Global Market by Plex
• Table 35 Global Market by Place
• Table 36 Respiratory by Country
• Table 37 Gastrointestinal by Country
• Table 38 Blood by Country
• Table 39 Meningitis/Encephalitis by Country
• Table 40 Sexually Transmitted Disease by Country
• Table 41 Other by Country
• Table 42 Single Plex by Country
• Table 43 Duplex by Country
• Table 44 Triplex by Country
• Table 45 Multiplex by Country
• Table 46 Hospital Lab by Country
• Table 47 Outpatient Lab by Country
• Table 48 POC by Country
• Table 49 Other by Country
• Table 50 2020 Clinical Lab Fee Schedule
• Table 51 COVID -19 Approved Assays

Table of Figures

• Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
• Figure 2 HIV Virion
• Figure 3 Diagram of the HIV Replication Cycle
• Figure 4 The Structure of the HBV Virus
• Figure 5 Hepatitis B Replication
• Figure 6 Structure of the HCV Virus
• Figure 7 HCV Replication Cycle
• Figure 8 Structure of the Influenza Virion
• Figure 9 Influenza Replication
• Figure 10 Scanning Electronmicrograph of Tuberculosis
• Figure 11 Percentage of World Population Over 65
• Figure 12 Chart Infectious Disease Decline
• Figure 13 Global Market Density Chart
• Figure 14 Global Market by Syndrome - Base vs. Final
• Figure 15 Global Market by Syndrome Base Year
• Figure 16 Global Market by Syndrome End Year
• Figure 17 Syndrome Share by Year
• Figure 18 Syndrome Segments Growth
• Figure 19 Global Market by Plex - Base vs. Final
• Figure 20 Global Market by Plex Base Year
• Figure 21 Global Market by Plex End Year
• Figure 22 Plex Share by Year
• Figure 23 Plex Segments Growth
• Figure 24 Global Market by Place - Base vs. Final
• Figure 25 Global Market by Place Base Year
• Figure 26 Global Market by Place End Year
• Figure 27 Place Share by Year
• Figure 28 Place Segments Growth
• Figure 29 Respiratory Growth
• Figure 30 Gastrointestinal Diagnostics Growth
• Figure 31 Blood Growth
• Figure 32 Meningitis/Encephalitis Growth
• Figure 33 Sexually Transmitted Disease Growth
• Figure 34 Other Growth
• Figure 35 Single Plex Growth
• Figure 36 Duplex Growth
• Figure 37 Triplex Growth
• Figure 38 Multiplex Growth
• Figure 39 Hospital Lab Growth
• Figure 40 Outpatient Lab Growth
• Figure 41 POC Growth
• Figure 42 Other Growth

OVERVIEW:

COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab my disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. Learn all about it in this new report from Howe Sound Research. A range of dynamic trends are pushing market growth and company valuations.

Trends like ......

• Multiplex testing
• pathogen evolution and pandemics
• biotechnology advances in genetics
• climate change
• globalization
• the rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

All report data is available in Excel format on request.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

• B.Sc. (Chemistry) University of BC
• M.B.A. (Finance and Policy) University of BC
• Market Research Seminar - Burke Institute
• Finance for Senior Executives - Harvard Business School

Table of Contents

i. Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19.

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

• 1.1 What is Molecular Diagnostics
• 1.2 The Diagnostics Revolution
• 1.3 Market Definition
  • 1.3.1 Revenues
• 1.4 Methodology
  • 1.4.1 Authors
  • 1.4.2 Sources
• 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
  • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Market Analysis by Disease

• 2.1 HIV - Human Immunodeficiency Virus (AIDS)
  • 2.1.1 Virology
    • 2.1.1.1 Classification
    • 2.1.1.2 Structure and genome
    • 2.1.1.3 Tropism
    • 2.1.1.4 Replication cycle
    • 2.1.1.5 Genetic variability
  • 2.1.2 Diagnosis
  • 2.1.3 Testing
    • 2.1.3.1 Antibody tests
    • 2.1.3.2 Point of Care Tests (POCT)
    • 2.1.3.4 Antigen Tests
    • 2.1.3.5 Nucleic acid-based tests (NAT)
    • 2.1.3.6 Other tests used in HIV treatment
  • 2.1.4 Market Opportunity Analysis
• 2.2 HBV - Hepatitis B
  • 2.2.1 Virology
    • 2.2.1.1 Genome
    • 2.2.1.2 Pathogenesis
    • 2.2.1.3 Hepatitis B virus replication
    • 2.2.1.4 Serotypes and genotypes
  • 2.2.2 Mechanisms
  • 2.2.3 Diagnosis
  • 2.2.4 Market Opportunity Analysis
• 2.3 HCV - Hepatitis C
  • 2.3.1 Taxonomy
  • 2.3.2 Structure
    • 2.3.2.2 Genome
  • 2.3.3 Molecular biology
  • 2.3.4 Replication
  • 2.3.5 Genotypes
    • 2.3.5.1 Clinical importance
  • 2.3.6 Market Opportunity Analysis
• 2.4 HPV - Human papillomavirus
  • 2.4.1 Virology
    • 2.4.1.1 E6/E7 proteins
    • 2.4.1.2 Role in cancer
    • 2.4.1.3 E2 research
    • 2.4.1.4 Latency period
    • 2.4.1.5 Clearance
  • 2.4.2 Diagnosis
    • 2.4.2.1 Cervical testing
    • 2.4.2.2 Oral testing
    • 2.4.2.3 Testing men
    • 2.4.2.4 Other testing
  • 2.4.3 Market Opportunity Analysis
• 2.5 Influenza
  • 2.5.1 Virology
    • 2.5.1.1 Types of virus
    • 2.5.1.2 Influenzavirus A
    • 2.5.1.3 Influenzavirus B
    • 2.5.1.4 Influenzavirus C
    • 2.5.1.5 Structure, properties, and subtype nomenclature
    • 2.5.1.6 Replication
  • 2.5.2 Testing
    • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
  • 2.5.3 Market Opportunity Analysis
• 2.6 CTGC - Chlamydia/Gonorhea
  • 2.6.1 Gonorrhea
    • 2.6.1.1 Diagnosis
    • 2.6.1.2 Screening
  • 2.6.2 Chlamydia
    • 2.6.2.1 Diagnosis
    • 2.6.2.2 Screening
  • 2.6.3 Testing
    • 2.6.3.1 Nucleic acid amplification tests (NAATs).
    • 2.6.3.2 Performance of NAAT Tests
  • 2.6.4 Market Opportunity Analysis
• 2.7 Tuberculosis
  • 2.7.1 Mycobacteria
  • 2.7.2 Diagnosis
    • 2.7.2.1 Active tuberculosis
    • 2.7.2.2 Latent tuberculosis
  • 2.7.3 Epidemiology
  • 2.7.4 Molecular Diagnostic Tests
  • 2.7.5 Market Opportunity Analysis
• 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
  • 2.8.1 Diagnosis
  • 2.8.2 FDA Approved Molecular Tests
  • 2.8.3 Market Opportunity Analysis
• 2.9 VRE - Vancomycin-resistant Enterococcus
  • 2.9.1 FDA Approved MDx Tests for VRE
  • 2.9.2 Market Opportunity Analysis
• 2.10 Blood Screening
  • 2.10.1 Collection and Testing
  • 2.10.2 FDA Approved Multiplex Assays
  • 2.10.3 Market Opportunity Analysis
• 2.11 COVID-19
  • 2.11.1 Signs and symptoms
  • 2.11.2 Transmission
  • 2.11.3 Diagnosis
  • 2.11.4 Prevention
  • 2.11.5 Management
  • 2.11.6 Prognosis
• 2.12 Pandemic Diagnostics
  • 2.12.1 Risk Management - Spark and Spread
  • 2.12.2 Dx Technology - Nucleic Acid Based
  • 2.12.3 Dx Technology - Immunoassay & Serology
  • 2.12.4 Time to Market and Preparedness Issues
  • 2.12.5 Unrecognized Role of Multiplex in Pandemic Mangement

3. Industry Overview

• 3.1 Players in a Dynamic Market
  • 3.1.1 Academic Research Lab
  • 3.1.2 Diagnostic Test Developer
  • 3.1.3 Instrumentation Supplier
  • 3.1.4 Distributor and Reagent Supplier
  • 3.1.5 Independent Testing Lab
  • 3.1.6 Public National/regional lab
  • 3.1.7 Hospital lab
  • 3.1.8 Physician Office Labs
  • 3.1.9 Audit Body
  • 3.1.10 Certification Body
• 3.2 The Clinical Laboratory Market Segments
  • 3.2.1 Traditional Market Segmentation
  • 3.2.2 Laboratory Focus and Segmentation
• 3.3 Industry Structure
  • 3.3.1 Hospital Testing Share
  • 3.3.2 Economies of Scale
    • 3.3.2.1 Hospital vs. Central Lab
  • 3.3.3 Physician Office Lab's
  • 3.3.4 Physician's and POCT
• 3.4 Profiles of Key MDx Companies
  • Abbott Diagnostics
  • Accelerate Diagnostics
  • Ador Diagnostics
  • Akonni Biosystems
  • Alveo Technologies
  • Applied BioCode
  • Atlas Genetics
  • Aus Diagnostics
  • BD Diagnostics
  • Beckman Coulter
  • Biocartis
  • bioMérieux
  • Bio-Rad Laboratories
  • Bosch Healthcare Solutions GmbH
  • Cepheid
  • Chembio
  • Curetis
  • Diagenode Diagnostics
  • DiaSorin
  • Eiken Chemical
  • Fusion Genomics.
  • Genedrive
  • GenePOC Diagnostics
  • GenMark Dx
  • Grifols
  • Hologic
  • Illumina
  • Inflammatix
  • Janssen Diagnostics
  • Karius
  • Lexagene
  • Luminex
  • Mbio Diagnostics
  • Meridian Bioscience
  • Mesa Biotech
  • Mobidiag
  • Nanomix
  • Oxford Nanopore Technologies
  • Panagene
  • Primerdesign
  • Prominex
  • Qiagen
  • Quantumdx
  • Quidel
  • Roche Molecular Diagnostics
  • Seegene
  • Siemens Healthineers
  • T2 Biosystems
  • Thermo Fisher
  • Veramarx
  • XCR Diagnostics

4. Market Trends

• 4.1 Factors Driving Growth
  • 4.1.1 New Genotypes Creating New Markets
  • 4.1.2 Aging Population a Boon for All Diagnostics
  • 4.1.3 Developing World Driving ID Dx Growth
  • 4.1.4 Point of Care - Why Centralization is Losing Steam
  • 4.1.5 Self Testing
  • 4.1.6 The Need for Speed
• 4.2 Factors Limiting Growth
  • 4.2.1 Lower Costs
  • 4.2.2 Infectious Disease is Declining
  • 4.2.3 Wellness Hurts
  • 4.2.4 Economic Growth improves Living Standards
• 4.3 Instrumentation and Automation
  • 4.3.1 Instruments Key to Market Share
  • 4.3.2 The Shrinking Machine.
  • 4.3.2 Multiplex, Point of Care and The Speed Factor
• 4.4 Diagnostic Technology Development
  • 4.4.1 The Sepsis Testing Market - A New Direction?
  • 4.4.2 POCT/Self Testing as a Disruptive Force
  • 4.4.3 The Genetics Play - One Test for All Known Infections
  • 4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

• Recent Developments - Importance and How to Use This Section
• Importance of These Developments
• How to Use This Section
• FDA Provides Self Testing SARS-CoV-2 EAU Guidance
• Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
• Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
• Qiagen Respiratory Panel with Coronavirus Receives CE Mark
• Lumos Diagnostics Closes $15M Series A Funding
• Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay
• New Genomic Tests Diagnose Deadly Infections Faster
• Biotia Raises $2.4M Seed Round
• STDs resurge in US
• Ares Genetics signs R&D agreement with leading global IVD corporation
• Cell-Free DNA Used for Infectious Disease Testing
• One BioMed Raises $5M
• FDA grants Qiagen clearance for syndromic testing system
• iCubate, Wondfo Biotech Form Chinese JV to Develop MDx Assays
• Researchers Launch CRISPR Dx Firm Sherlock Biosciences
• Israel's BATM to Invest up to $30M in Ador Diagnostics
• Superbug Test from Mobidiag Gets CE Mark
• Akonni Biosystems Submits Multiplex Diagnostics System to FDA
• Mesa Biotech RSV Test Wins CE Mark
• Karius Test to Be Available in Brazil
• Panagene's STD kit gains Approval
• Startup Prominex Raises $4M in Series A1
• GenePOC's Investment Validated by Medicare Decision
• GenePOC® launches its GenePOC® CDiff test in Canada
• NYU researchers adapt HIV test to Zika virus
• GA-EMS receives diagnostic device contract
• Biocartis & Immunexpress Sign Partnership for Sepsis
• PerkinElmer to Acquire Euroimmun for $1.3B
• Alveo Closes Financing to Create Accessible Diagnostics Devices
• Siemens Healthineers completes takeover of Fast Track Diagnostics
• Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
• Chembio and FIND to Develop Point-of-Care Multiplex Test
• Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test
• Alere bags FDA nod for rapid flu diagnostic
• FDA approves tests of tick-borne disease to protect blood supply
• Qiagen Trichomonas Assay Gets CE Mark
• Vela Diagnostics HSV Test Gets FDA Clearance
• QIAGEN enters into agreement to acquire STAT-Dx
• Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
• Applied BioCode's Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
• Ares Genetics to develop AI diagnostic test for infectious diseases
• FDA Considers Guidelines for NGS-Based Infectious Disease Diagnostics

6. The Global Market for Molecular Diagnostics Infectious Disease

• 6.1 Global Market Overview by Country
  • 6.1.1 Table - Global Market by Country
  • 6.1.2 Chart - Global Market by Country
• 6.2 Global Market by Syndrome - Overview
  • 6.2.1 Table - Global Market by Syndrome
  • 6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
  • 6.2.3 Chart - Global Market by Syndrome - Base Year
  • 6.2.4 Chart - Global Market by Syndrome - End Year
  • 6.2.5 Chart - Global Market by Syndrome - Share by Year
  • 6.2.6 Chart - Global Market by Syndrome - Segments Growth
• 6.3 Global Market by Plex - Overview
  • 6.3.1 Table - Global Market by Plex
  • 6.3.2 Chart - Global Market by Plex - Base/Final Year Comparison
  • 6.3.3 Chart - Global Market by Plex - Base Year
  • 6.3.4 Chart - Global Market by Plex - End Year
  • 6.3.5 Chart - Global Market by Plex - Share by Year
  • 6.3.6 Chart - Global Market by Plex - Segments Growth
• 6.4 Global Market by Place - Overview
  • 6.4.1 Table - Global Market by Place
  • 6.4.2 Chart - Global Market by Place - Base/Final Year Comparison
  • 6.4.3 Chart - Global Market by Place - Base Year
  • 6.4.4 Chart - Global Market by Place - End Year
  • 6.4.5 Chart - Global Market by Place - Share by Year
  • 6.4.6 Chart - Global Market by Place - Segments Growth

7. Global MDx Infectious Disease Markets - By Syndrome

• 7.1 Respiratory
  • 7.1.1 Table Respiratory - by Country
  • 7.1.2 Chart - Respiratory Growth
• 7.2 Gastrointestinal
  • 7.2.1 Table Gastrointestinal - by Country
  • 7.2.2 Chart - Gastrointestinal Growth
• 7.3 Blood
  • 7.3.1 Table Blood - by Country
  • 7.3.2 Chart - Blood Growth
• 7.4 Meningitis/Encephalitis
  • 7.4.1 Table Meningitis/Encephalitis - by Country
  • 7.4.2 Chart - Meningitis/Encephalitis Growth
• 7.5 Sexually Transmitted Disease
  • 7.5.1 Table Sexually Transmitted Disease - by Country
  • 7.5.2 Chart - Sexually Transmitted Disease Growth
• 7.6 Other
  • 7.6.1 Table Other - by Country
  • 7.6.2 Chart - Other Growth

8. Global MDx Markets for Infectious Disease - by Plex

• 8.1 Single Plex
  • 8.1.1 Table Single Plex - by Country
  • 8.1.2 Chart - Single Plex Growth
• 8.2 Duplex
  • 8.2.1 Table Duplex - by Country
  • 8.2.2 Chart - Duplex Growth
• 8.3 Triplex
  • 8.3.1 Table Triplex - by Country
  • 8.3.2 Chart - Triplex Growth
• 8.4 Multiplex Technology
  • 8.4.1 Table Multiplex - by Country
  • 8.4.2 Chart - Multiplex Growth

9. Global MDx Infectious Disease Markets - by Place

• 9.1 Hospital Lab
  • 9.1.1 Table Hospital Lab - by Country
  • 9.1.2 Chart - Hospital Lab Growth
• 9.2 Outpatient Lab
  • 9.2.1 Table Outpatient Lab - by Country
  • 9.2.2 Chart - Outpatient Lab Growth
• 9.3 POC
  • 9.3.1 Table POC - by Country
  • 9.3.2 Chart - POC Growth
• 9.4 Other Technology
  • 9.4.1 Table Other - by Country
  • 9.4.2 Chart - Other Growth

Appendices

• I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
• II. COVID-19 Approved Assays